| Dr Mirza Umair Baig, MD | |
|
6901 N Charles St, Baltimore, MD 21204-3780 | |
| (410) 849-2226 | |
| Not Available |
| Full Name | Dr Mirza Umair Baig |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 6901 N Charles St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063770832 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | D77868 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Greater Baltimore Medical Center | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America Llc | 6608056171 | 575 |
News Archive
Complex, multi-system diseases like myotonic dystrophy - the most common adult form of muscular dystrophy - require physicians and patients to identify which symptoms impact quality of life and, consequently, what treatments should take priority. However, a new study out this month in the journal Neurology reveals that there is often a disconnect between the two groups over which symptoms are more important, a phenomenon that not only impacts care but also the direction of research into new therapies.
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
The Food and Drug Administration (FDA) has given the Blanchette Rockefeller Neurosciences Institute (BRNI) the go-ahead to conduct Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients.
Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.
Children's genetic risks for obesity may be reduced by interventions that strengthen family communication and help children manage their emotions and feelings of satiety, according to a new review of research on the problem.
› Verified 2 days ago
| Entity Name | Cep America Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821434002 PECOS PAC ID: 6608056171 Enrollment ID: O20130621000257 |
News Archive
Complex, multi-system diseases like myotonic dystrophy - the most common adult form of muscular dystrophy - require physicians and patients to identify which symptoms impact quality of life and, consequently, what treatments should take priority. However, a new study out this month in the journal Neurology reveals that there is often a disconnect between the two groups over which symptoms are more important, a phenomenon that not only impacts care but also the direction of research into new therapies.
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
The Food and Drug Administration (FDA) has given the Blanchette Rockefeller Neurosciences Institute (BRNI) the go-ahead to conduct Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients.
Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.
Children's genetic risks for obesity may be reduced by interventions that strengthen family communication and help children manage their emotions and feelings of satiety, according to a new review of research on the problem.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mirza Umair Baig, MD 6901 N Charles St, Baltimore, MD 21204-3780 Ph: (410) 849-2226 | Dr Mirza Umair Baig, MD 6901 N Charles St, Baltimore, MD 21204-3780 Ph: (410) 849-2226 |
News Archive
Complex, multi-system diseases like myotonic dystrophy - the most common adult form of muscular dystrophy - require physicians and patients to identify which symptoms impact quality of life and, consequently, what treatments should take priority. However, a new study out this month in the journal Neurology reveals that there is often a disconnect between the two groups over which symptoms are more important, a phenomenon that not only impacts care but also the direction of research into new therapies.
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
The Food and Drug Administration (FDA) has given the Blanchette Rockefeller Neurosciences Institute (BRNI) the go-ahead to conduct Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients.
Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.
Children's genetic risks for obesity may be reduced by interventions that strengthen family communication and help children manage their emotions and feelings of satiety, according to a new review of research on the problem.
› Verified 2 days ago
Ankita Taneja, MD, MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2079 | |
Scott Mcpherson, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 301 Saint Paul Pl, Baltimore, MD 21202 Phone: 410-332-9809 | |
Larry Weiss, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-4383 | |
Shannon Brandy Putman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-2280 | |
Arjun S Chanmugam, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-2280 | |
Dr. Donald W Alves, MD, MS, FACEP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1201 Reisterstown Road, Medical Services, Baltimore, MD 21208 Phone: 410-653-8366 Fax: 410-653-4290 | |
Michael Rayner Leedom, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Emergency Dept, Baltimore, MD 21201 Phone: 410-328-8025 Fax: 410-328-8028 |